Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

The Effect of Dulaglutide on Major Cardiovascular Events in Patients with Type 2 Diabetes: Researching Cardiovascular Events with a Weekly INcretin in Diabetes (REWIND)

Trial Profile

The Effect of Dulaglutide on Major Cardiovascular Events in Patients with Type 2 Diabetes: Researching Cardiovascular Events with a Weekly INcretin in Diabetes (REWIND)

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 26 Jun 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Dulaglutide (Primary)
  • Indications Cardiovascular disorders; Myocardial infarction; Stroke; Type 2 diabetes mellitus
  • Focus Registrational; Therapeutic Use
  • Acronyms REWIND
  • Sponsors Eli Lilly and Company
  • Most Recent Events

    • 12 Jun 2023 Results of exploratory post hoc analysis assessing kidney function-related outcomes, excluding the new-onset macroalbuminuria component published in the Diabetes Care
    • 10 Mar 2023 Results of post hoc analysis assessing the relationship of selected biomarkers to both dulaglutide and major adverse cardiovascular events, published in the Diabetes Care.
    • 13 Feb 2023 Results of post-hoc analysis assessing use of cardioprotective therapies for type 2 diabetes varies by gender and whether the risk of cardiovascular events is higher in women versus men, published in the Scandinavian Cardiovascular Journal.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top